Medicare Advantage
  
MPNewsFlashTopicPub
  
  
MPPurposePub
  
  
3/10/2021
Telehealth Services for Medicare Advantage Members (Updated February 10, 2021)
0.1

The purpose of this document is to provide advance notice regarding coverage for telehealth services for our Medicare Advantage members in response to Coronavirus Disease 2019 (COVID-19).
Telehealth Services for Medicare Advantage Members (Updated February 10, 2021)a4cd6188-c550-465a-98de-0ed4964361a2
3/1/2021
Coverage of COVID-19 Vaccination for Medicare Advantage Members (Updated March 1, 2021)
0.1

The purpose of this communication is to provide notice regarding information ​and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for Medicare Advantage members.​
Coverage of COVID-19 Vaccination for Medicare Advantage Members (Updated March 1, 2021)3ac2169a-38f4-4449-afbf-7ecfbfd2984d
1/25/2021
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated January 25, 2021)
0
The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage members.
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Medicare Advantage Members (Updated January 25, 2021)79613c77-03c9-47fd-90c5-5860b7a46132
1/4/2021
1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Medicare Advantage Products
0
The intent of this document is to communicate Medicare Advantage Product coverage determinations for services identified through the Annual Code Update process. 


1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Medicare Advantage Products83b993ed-7be0-47bc-983e-86d958abfdc6
12/31/2020
Medicare Diabetes Prevention Program in Response to COVID-19 Outbreak (Updated 12/31/2020)
0
The purpose of this NewsFLASH is to provide advance notice regarding coverage for Medicare diabetes prevention program in response to Coronavirus Disease 2019 (COVID-19).

This NewsFLASH addressing Medicare diabetes prevention program is effective for the duration of the public health emergency.

This policy communication addressing telehealth services for Medicare Advantage members has been updated  January 1, 2021 to remove the requirement of a documented 5% weight loss.
Medicare Diabetes Prevention Program in Response to COVID-19 Outbreak (Updated 12/31/2020)668d5e4b-58c4-42b2-bd67-219a209219e7
12/30/2020
Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of Independence Medicare Advantage Members (Updated December 30, 2020)
0

The purpose of this document is to communicate the Company's coverage position for Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 treatment of Independence Medicare Advantage members. 

This communication addressing Treatments for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) is effective from October 22, 2020 through March 31, 2021, or for the duration of the public health emergency. 

This document includes the following updates to the version that was published on November 25, 2020:

  • The name of this communication was changed FROM Veklury® (remdesivir) and Bamlanivimab® (LY-CoV555) for COVID-19 Treatment TO Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment.
  • Combination of Olumiant® (baricitinib)) and Veklury® (remdesivir) for COVID-19 Treatment, including coverage statement, was addressed per FDA Emergency Use Authorization (EUA) for this combination therapy.
  • Combination of Casirivimab/Imdevimab for COVID-19 Treatment, including coverage statement and procedure codes, was addressed per FDA EUA for this combination therapy.
 
Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of Independence Medicare Advantage Members (Updated December 30, 2020)9c4fbda7-fad8-48bb-afb8-c998325f22cc
10/1/2020
10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products
0.1
The intent of this article is to communicate Medicare Advantage Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2020, unless otherwise noted. 

For more information related to these services, please refer to specific policies when applicable.​



10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Productseaaa732d-9e1b-4325-a3d9-2891b122930a
7/17/2020
Respiratory Equipment and Related Supplies (updated July 17, 2020)
1
The purpose of this News Article is to provide advance notice during the COVID-19 outbreak related to respiratory equipment and related supplies.
Respiratory Equipment and Related Supplies (updated July 17, 2020)9501C49E786EA93E852585A7007B12E0
7/17/2020
Consumer Grade Pulse Oximetry Devices For Use In The Home Setting
1
The purpose of this News Article is to provide advance notice during the COVID-19 outbreak related to the coverage of consumer grade pulse oximetry devices for use in the home setting.
Consumer Grade Pulse Oximetry Devices For Use In The Home Setting6C97385C22DEF1EC852585A7007B19D5
7/1/2020
7/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage Products
1
7/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Medicare Advantage ProductsBC325E22B96FD1D585258598006632FB
1 - 10Next